EP1018344A3 - HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus - Google Patents

HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus Download PDF

Info

Publication number
EP1018344A3
EP1018344A3 EP00102538A EP00102538A EP1018344A3 EP 1018344 A3 EP1018344 A3 EP 1018344A3 EP 00102538 A EP00102538 A EP 00102538A EP 00102538 A EP00102538 A EP 00102538A EP 1018344 A3 EP1018344 A3 EP 1018344A3
Authority
EP
European Patent Office
Prior art keywords
hbv
hla
peptides
restricted
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00102538A
Other languages
English (en)
French (fr)
Other versions
EP1018344A2 (de
Inventor
Maria A. Vitiello
Robert W. Chesnut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1018344A2 publication Critical patent/EP1018344A2/de
Publication of EP1018344A3 publication Critical patent/EP1018344A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP00102538A 1991-08-26 1992-08-26 HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus Withdrawn EP1018344A3 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US749568 1991-08-26
US82768292A 1992-01-29 1992-01-29
US827682 1992-01-29
US87449192A 1992-04-27 1992-04-27
US874491 1992-04-27
EP92307764A EP0534615B1 (de) 1991-08-26 1992-08-26 Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP92307764A Division EP0534615B1 (de) 1991-08-26 1992-08-26 Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons

Publications (2)

Publication Number Publication Date
EP1018344A2 EP1018344A2 (de) 2000-07-12
EP1018344A3 true EP1018344A3 (de) 2000-09-20

Family

ID=27419385

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00102538A Withdrawn EP1018344A3 (de) 1991-08-26 1992-08-26 HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
EP92307764A Expired - Lifetime EP0534615B1 (de) 1991-08-26 1992-08-26 Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP92307764A Expired - Lifetime EP0534615B1 (de) 1991-08-26 1992-08-26 Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons

Country Status (16)

Country Link
EP (2) EP1018344A3 (de)
JP (2) JP3738395B2 (de)
AU (1) AU687725B2 (de)
BG (1) BG98523A (de)
CA (1) CA2115839C (de)
CZ (1) CZ42794A3 (de)
DE (1) DE69231621T2 (de)
ES (1) ES2155060T3 (de)
FI (1) FI940918A (de)
GR (1) GR3035575T3 (de)
HU (1) HUT68510A (de)
IL (1) IL102964A0 (de)
NO (1) NO940660L (de)
NZ (2) NZ244103A (de)
OA (1) OA09888A (de)
WO (1) WO1993003764A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
JP3795914B2 (ja) * 1993-04-27 2006-07-12 ユナイテッド・バイオメディカル・インコーポレイテッド ワクチン用免疫原性ｌｈｒｈペプチド構築体および合成普遍免疫刺激器
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
JP3926839B2 (ja) * 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
CA2286478A1 (en) * 1997-04-11 1998-10-22 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
DK1230268T3 (da) 1999-11-18 2010-02-08 Epimmune Inc Heteroklitiske analoger af klasse I-epitoper
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1740601B1 (de) * 2004-04-21 2012-12-05 The University of Chicago Myosin-leichte-kette-kinase inhibitoren und deren verwendung
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
EP2695895A1 (de) 2006-10-17 2014-02-12 Oncotherapy Science, Inc. Peptidvakzinen für MPHOSPH1- oder DEPDC1-Polypeptide exprimierenden Krebs
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CN110075113A (zh) * 2008-04-17 2019-08-02 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
CA2842887C (en) 2011-08-12 2021-01-19 Oncotherapy Science, Inc. Mphosph1 peptides and vaccines including the same
SG11201400432VA (en) * 2011-09-06 2014-08-28 Agency Science Tech & Res Polypeptide vaccine
JP2015530413A (ja) 2012-09-21 2015-10-15 ベデュ−アッド，フランク 改良されたワクチン組成物および使用方法
CN103961306A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
CA2840974A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
JP6934250B2 (ja) 2015-08-12 2021-09-15 オンコセラピー・サイエンス株式会社 Ｄｅｐｄｃ１由来ペプチドおよびそれを含むワクチン
JP6876682B2 (ja) * 2015-09-08 2021-05-26 ウニヴェルズィテート チューリッヒ ネコアレルギーに対する組成物
SG11201802286PA (en) 2015-10-08 2018-04-27 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same
EP4092112A1 (de) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271302A2 (de) * 1986-12-09 1988-06-15 Scripps Clinic And Research Foundation T-Zell-Epitope von Hepatitis-B-Virus-Nukleocapsid-Protein
EP0433242A1 (de) * 1989-10-16 1991-06-19 Fondazione Andrea Cesalpino Impfstoffe und Verfahren zu deren Herstellung
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271302A2 (de) * 1986-12-09 1988-06-15 Scripps Clinic And Research Foundation T-Zell-Epitope von Hepatitis-B-Virus-Nukleocapsid-Protein
EP0433242A1 (de) * 1989-10-16 1991-06-19 Fondazione Andrea Cesalpino Impfstoffe und Verfahren zu deren Herstellung
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. FERRARI ET AL.: "Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen", JOURNAL OF CLINICAL INVESTIGATION, vol. 88, no. 1, July 1991 (1991-07-01), pages 214 - 222, XP000923045 *
GLENN Y. ISHIOKA ET AL.: "Class I MHC-restricted, peptide-specific cytotoxic T lymphocytes generated by peptide priming in vivo", VACCINES, 1990, pages 7 - 11, XP000923050 *
K.H. WIESMÜLLER ET AL.: "Lipopeptide-helper T-cell epitope-CTL epitope conjugate induces antibodies against the CTL epitope", INNOVATION PERSPECT. SOLID-PHASE SYNTH. COLLECT. PAPERS, INT. SYMP. 2ND 1991, 1991, pages 499 - 502 *
KARL DERES ET AL.: "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine", NATURE, vol. 342, no. 6249, 30 November 1989 (1989-11-30), LONDON GB, pages 561 - 564, XP002142260 *
TAKAJI WAKITA ET AL.: "Gamma-interferon production in response to hepatitis B core protein and its synthetic peptides in patients with chronic hepatitis B virus infection", DIGESTION, vol. 47, 1990, pages 149 - 155, XP000923047 *

Also Published As

Publication number Publication date
GR3035575T3 (en) 2001-06-29
DE69231621T2 (de) 2001-05-31
JPH06510051A (ja) 1994-11-10
ES2155060T3 (es) 2001-05-01
OA09888A (en) 1994-09-15
FI940918A (fi) 1994-04-08
NZ244103A (en) 1997-07-27
EP1018344A2 (de) 2000-07-12
HUT68510A (en) 1995-06-28
CZ42794A3 (en) 1994-11-16
NO940660L (no) 1994-04-22
NO940660D0 (no) 1994-02-25
JP3586278B2 (ja) 2004-11-10
EP0534615B1 (de) 2001-01-03
CA2115839C (en) 2010-06-01
IL102964A0 (en) 1993-01-31
CA2115839A1 (en) 1993-03-04
FI940918A0 (fi) 1994-02-25
AU687725B2 (en) 1998-03-05
NZ270605A (en) 1997-07-27
DE69231621D1 (de) 2001-02-08
EP0534615A2 (de) 1993-03-31
WO1993003764A1 (en) 1993-03-04
JP2004075693A (ja) 2004-03-11
EP0534615A3 (en) 1994-05-25
BG98523A (en) 1995-05-31
AU2548792A (en) 1993-03-16
HU9400581D0 (en) 1994-05-30
JP3738395B2 (ja) 2006-01-25

Similar Documents

Publication Publication Date Title
EP1018344A3 (de) HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
Zanetti et al. The global impact of vaccination against hepatitis B: a historical overview
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
DK0726758T3 (da) Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
AP1771A (en) 3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
WO1994006913A3 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
RU93053037A (ru) Вакцина против заболевания сумки птиц и способы лечения
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
DE60229126D1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
EP0542753A4 (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
PETERSON et al. Immune response to hepatitis viruses
Parkman et al. Viral vaccines and antivirals: current use and future prospects
Jilg et al. Vaccination against hepatitis B—The current situation
Machida et al. Anti-preS2 neutralizes the hepatitis B virus variant with a vaccine-escape mutation at the amino acid position 126 or 145 within the S gene
FI930519A (fi) Peptider foer blokering av infektioner orsakade av hiv-virus samt foerfarande foer deras anvaendnig
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
Karra et al. 64. DIAGNOSIS & MANAGEMENT OF HEPATITIS B
Sangfelt Prevention and treatment of hepatitis B virus infection
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
Shah et al. High‐Risk Needle Exposure in Hepatitis B Vaccine Failures: What are the Options?
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
ES8605576A1 (es) Un procedimiento para preparar una composicion contra infecciones virales de hepatitis b

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000223

AC Divisional application: reference to earlier application

Ref document number: 534615

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/51 A, 7A 61K 39/29 B, 7G 01N 33/569 B, 7C 07K 7/00 B

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AKX Designation fees paid

Free format text: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIMMUNE INC.

17Q First examination report despatched

Effective date: 20050121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050801